Drug class in one race
TROP2 drugs for Non-Small Cell Lung Cancer
7 tracked TROP2 drugs in the Non-Small Cell Lung Cancer race. The class explanation lives on the TROP2 page; the full indication pipeline across every mechanism is on the Non-Small Cell Lung Cancer page.
1 approved / phase 42 Phase 31 Phase 1/23 preclinical / unstaged
Head-to-head evidence: BL-M02D1 vs Datopotamab Deruxtecan · Datopotamab Deruxtecan vs DB-1305 · Datopotamab Deruxtecan vs LCB84 · Datopotamab Deruxtecan vs MT-302 · Datopotamab Deruxtecan vs Sacituzumab Govitecan · Datopotamab Deruxtecan vs Sacituzumab Tirumotecan